Introduction {#S0001}
============

Coronary artery disease (CAD) is the leading cause of death and disability worldwide \[[1](#CIT0001),[2](#CIT0002)\]. So far, the exact pathogenesis of CAD is still unclear. Nevertheless, plenty of evidence supported that genetic factors may play a crucial part in its development. First, family clustering of CAD was observed extensively, and past twin studies proved that the heredity grade of CAD was over 50% \[[3](#CIT0003),[4](#CIT0004)\]. Second, numerous genetic variants were found to be associated with an increased susceptibility to CAD by previous genetic association studies, and screening of common causal variants was also proved to be an efficient way to predict the individual risk of developing CAD \[[5](#CIT0005),[6](#CIT0006)\]. Overall, these findings jointly supported that genetic predisposition to CAD is important for its occurrence and development.

Adiponectin (ADIPOQ), a multifunctional adipocytokine that is predominantly secreted by adipocytes, plays a central role in regulating energy and material metabolism \[[7](#CIT0007)\]. Previous studies showed that adiponectin has both anti-atherogenic and anti-inflammatory properties \[[8](#CIT0008),[9](#CIT0009)\]. Furthermore, the expression level of adiponectin was also significantly decreased in patients with CAD \[[10](#CIT0010),[11](#CIT0011)\]. In summary, these pieces of evidence jointly suggested that adiponectin might exert favourable protection effects against CAD. Therefore, functional *ADIPOQ* genetic polymorphisms, which may alter the expression level of adiponectin, may also affect individual susceptibility to CAD. So far, several studies already tried to investigate associations between *ADIPOQ* polymorphisms and CAD, but the results of these studies were controversial, especially when they were conducted in different populations \[[12](#CIT0012)--[19](#CIT0019)\]. Previous studies failed to reach a consensus regarding associations between *ADIPOQ* polymorphisms and CAD partially because of their relatively small sample sizes. Thus, we performed the present meta-analysis to explore the relationship between *ADIPOQ* polymorphisms and CAD in a larger pooled sample size. Additionally, we also aimed to elucidate the potential effects of ethnic background on associations between *ADIPOQ* polymorphisms and CAD.

Materials and methods {#S0002}
=====================

Literature search and inclusion criteria {#S0002-S2001}
----------------------------------------

The current meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist \[[20](#CIT0020)\]. PubMed, Web of Science, Embase and China National Knowledge Infrastructure (CNKI) were searched for potentially eligible articles using the combination of following terms: (adiponectin OR ADIPOQ) AND (polymorphism OR variant OR mutation OR genotype OR allele) AND (coronary heart disease OR coronary artery disease OR angina pectoris OR acute coronary syndrome OR myocardial infarction). We also reviewed the reference lists of all retrieved articles to identify other potentially eligible studies. The initial search was conducted in July 2018 and the latest update was performed in December 2018.

To test the research hypothesis of this meta-analysis, included studies must satisfy the following criteria: (1) case--control study on associations between *ADIPOQ* polymorphisms and CAD; (2) provide genotypic and/or allelic frequency of investigated *ADIPOQ* polymorphisms; and (3) full text in English or Chinese available. Studies were excluded if one of the following criteria was fulfilled: (1) not relevant to *ADIPOQ* polymorphisms and CAD; (2) case reports or case series; and (3) abstracts, reviews, comments, letters and conference presentations. In the case of duplicate reports by the same authors, we only included the most recent study for analyses.

Data extraction and quality assessment {#S0002-S2002}
--------------------------------------

We extracted the following information from eligible studies: (a) name of the first author; (b) year of publication; (c) country and ethnicity of participants; (d) sample size; and (e) genotypic distributions of *ADIPOQ* polymorphisms in cases and controls. The probability value (*p* value) of Hardy--Weinberg equilibrium (HWE) was also calculated.

We used the Newcastle--Ottawa scale (NOS) to evaluate the quality of eligible studies \[[21](#CIT0021)\]. The NOS has a score range of 0 to 9, and studies with a score of more than 7 were thought to be of high quality.

Two reviewers conducted data extraction and quality assessment independently. When necessary, we wrote to the corresponding authors for extra information. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

Statistical analyses {#S0002-S2003}
--------------------

In the current study, we performed statistical analyses by using Review Manager Version 5.3.3. We calculated ORs and 95% CIs to estimate potential associations between *ADIPOQ* polymorphisms and CAD in dominant, recessive, overdominant and allele models, and statistical significances of pooled analyses were determined by the *Z* test, with a *p* value of 0.05 or less was defined as statistically significant. All investigated *ADIPOQ* polymorphisms contain a major allele (M) and a minor allele (m), and the definitions of all genetic comparisons were as follows: dominant comparison is defined as MM versus Mm + mm, recessive comparison is defined as mm vs. MM +Mm, overdominant comparison is defined as Mm versus MM + mm, and the allele comparison is defined as M versus m. Between-study heterogeneities were evaluated by *I*^2^ statistic. Random-effect models would be used for analyses if *I*^2^ was greater than 50% (Der Simonian--Laird method). Otherwise, analyses would be conducted with fixed-effect models (Mantel--Haenszel method). Subgroup analyses were subsequently carried out by ethnicity and type of disease. Stabilities of synthetic results were tested in sensitivity analyses. Publication biases were assessed by funnel plots.

Results {#S0003}
=======

Characteristics of included studies {#S0003-S2001}
-----------------------------------

We found 434 potentially relevant articles. Among these articles, totally 51 eligible studies were finally included for synthetic analyses (see [Figure 1](#F0001)). The NOS score of eligible articles ranged from 7 to 8, which indicated that all the included studies were of high quality. Baseline characteristics of the included studies are summarized in [Table 1](#T0001).10.1080/21623945.2019.1595270-T0001Table 1.The characteristics of included studies.First author, yCountryEthnicityType of diseaseSample sizeGenotype distribution*p*-Value for HWENOS scoreCase--controls**rs266729 G/C**    CC/CG/GG  Cheung 2014Hong KongEast AsianCAD184/2007111/65/81148/729/1300.3277Chiodini 2010ItalyCaucasianMI1002/503583/353/66321/160/220.7177De Caterina 2011ItalyCaucasianMI1855/18551076/671/1081063/684/1080.8837Du 2016ChinaEast AsianCAD493/304278/175/40219/73/120.0698Gable 2007UKCaucasianMI530/564278/217/35329/197/380.2548Hegener 2006USAMixedMI340/342197/123/20188/134/200.5438Lacquemant 2004UKCaucasianCAD161/31389/65/7174/118/210.8707Oguri 2009JapanEast AsianMI773/1114397/336/40675/379/600.4787Persson 2010SwedenCaucasianMI244/244127/100/17130/101/130.2418Prior 2009UKCaucasianCAD155/60989/56/10335/242/320.1658Prior 2011UKCaucasianCAD85/29846/38/1158/114/260.4068Rodr´ıguez-Rodr´ıguez 2011SpainCaucasianCAD119/55567/46/6327/188/400.0767Zhang 2015ChinaEast AsianCAD561/412305/228/28212/172/280.3838Zhang 2018ChinaEast AsianCAD717/612345/306/66301/253/580.6488Zhao 2018ChinaEast AsianCAD1044/1349590/385/69774/498/770.7918Zhong 2010ChinaEast AsianCAD198/237110/72/16146/76/150.2398**rs822395 A/C**    AA/AC/CC  Cheung 2014Hong KongEast AsianCAD184/2009130/53/11441/527/410.3717De Caterina 2011ItalyCaucasianMI1855/1854848/811/196867/806/1810.7507Lacquemant 2004UKCaucasianCAD162/31175/69/18138/141/320.6477Pischon 200USAMixedCAD496/989223/208/65450/467/720.0017Qi 2005USAMixedCAD234/626104/101/29270/280/760.7957Zhang 2015ChinaEast AsianCAD535/396408/119/8274/114/80.3288Zhang 2018ChinaEast AsianCAD717/612295/307/115252/281/790.9628Zhong 2010ChinaEast AsianCAD198/237143/48/7175/59/30.4248**rs1501299 G/T**    GG/GT/TT  Al-Daghri 2011Saudi ArabiaSouth AsianCAD123/29747/57/19111/142/440.8977Ambroziak 2018PolandCaucasianMI188/15388/72/2884/59/100.9337Antonopoulos 2013GreeceCaucasianCAD462/132220/212/3066/50/160.1848Bacci 2004ItalyCaucasianCAD142/23470/65/7118/88/280.0737Boumaiza 2011TunisiaCaucasianCAD213/108105/84/2345/41/180.1158Chen 2011ChinaEast AsianCAD93/10254/33/661/38/30.3077Cheung 2014Hong KongEast AsianCAD182/201088/75/191103/759/1480.2707Chiodini 2010ItalyCaucasianMI1002/503530/392/80239/198/660.0167De Caterina 2011ItalyCaucasianMI1833/1821926/746/161906/767/1480.4197Esteghamati 2012IranSouth AsianCAD114/12776/30/863/47/170.0957Filippi 2005ItalyCaucasianCAD580/466287/241/52266/167/330.3388Gable 2007UKCaucasianMI504/557266/216/22289/225/430.9318Ghazouani 2018TunisiaCaucasianCAD277/269143/93/41138/88/43\<0.0018Gui 2012ChinaEast AsianCAD410/431172/185/53239/154/380.0728Hegener 2006USAMixedMI341/341183/134/24181/143/170.0938Jung 2006KoreaEast AsianCAD88/6838/43/731/32/50.3997Katakami 2012JapanEast AsianMI213/2424129/71/131229/976/2190.2097Lacquemant 2004UKCaucasianCAD161/30982/66/13169/115/250.3877Li 2018ChinaEast AsianCAD201/14167/107/2764/53/240.0308Liang 2011ChinaEast AsianMI78/8430/43/548/30/60.6637Liang 2017ChinaEast AsianCAD960/962490/388/82617/300/450.2758Mohammadzadeh 2016IranSouth AsianCAD100/10038/55/756/42/20.0637Ohashi 2004JapanEast AsianCAD383/368185/164/34190/149/290.9778Oliveira 2012BrazilMixedCAD450/153209/197/4462/68/230.5427Pischon 2007USAMixedCAD491/988266/182/43485/416/870.8697Qi 2005USAMixedCAD228/594105/111/12293/249/520.9307Rizk 2012QatarSouth AsianACS142/12158/64/2046/59/160.6677Rodr´ıguez-Rodr´ıguez 2011SpainCaucasianCAD119/55569/44/6287/224/440.9757Wu 2013ChinaEast AsianCAD188/20067/108/1392/90/180.5457Zhang 2015ChinaEast AsianCAD561/412309/209/43214/170/280.4598Zhang 2018ChinaEast AsianCAD717/612583/126/8471/131/100.7988**rs2241766 T/G**    TT/TG/GG  Al-Daghri 2011Saudi ArabiaSouth AsianCAD122/29877/35/10220/72/60.9697Antonopoulos 2013GreeceCaucasianCAD462/132359/97/699/29/40.3098Bacci 2004ItalyCaucasianCAD130/22090/35/5149/60/110.1357Boumaiza 2011TunisiaCaucasianCAD212/104145/57/1075/24/50.1118Chang 2009TaiwanEast AsianCAD600/687316/238/46309/399/790.6067Chen 2011ChinaEast AsianCAD93/10268/19/659/35/80.3917Cheung 2014Hong KongEast AsianCAD184/201289/83/121007/822/1830.4137Chiodini 2010ItalyCaucasianMI1002/503679/304/19359/126/180.1027Di 2011ChinaEast AsianCAD196/12491/85/2065/50/90.8847Du 2016ChinaEast AsianCAD493/304253/190/50185/97/220.0698Esteghamati 2012IranSouth AsianCAD114/12748/41/2568/46/130.2227Foucan 2010French West IndiesAfricanCAD57/159NANANA7Gable 2007UKCaucasianMI526/563360/154/12384/168/110.2808Ghazouani 2018TunisiaCaucasianCAD277/269181/74/22182/70/170.0078Hegener 2006USAMixedMI341/341241/95/5252/80/90.3898Jin 2009ChinaEast AsianCAD110/7353/48/950/20/30.5848Jung 2006KoreaEast AsianCAD88/6841/40/734/30/40.4317Lacquemant 2004UKCaucasianCAD162/315109/48/5249/57/90.0157Li 2011ChinaEast AsianCAD118/9751/46/2154/31/120.0368Liang 2017ChinaEast AsianCAD960/982471/382/107608/308/460.3878Luo 2010ChinaEast AsianCAD221/100100/99/2250/41/90.8867Mofarrah 2016IranSouth AsianCAD152/7282/35/3556/13/30.0728Mohammadzadeh 2016IranSouth AsianCAD100/10075/24/165/31/40.9007Nan 2012ChinaEast AsianCAD213/467115/84/14237/191/390.9538Oliveira 2012BrazilMixedCAD450/153323/114/13117/33/30.7087Pischon 2007USAMixedCAD482/979374/102/6759/202/180.2907Qi 2005USAMixedCAD219/599NANANA7Rizk 2012QatarSouth AsianACS142/12262/42/3856/49/170.2457Sabouri 2011IranSouth AsianCAD329/241253/74/2205/35/10.7037Xu 2010ChinaEast AsianCAD153/7378/65/1050/20/30.5848Zhang 2011ChinaEast AsianCAD149/16763/60/2697/50/200.0027Zhang 2015ChinaEast AsianCAD561/412276/235/50224/164/240.3998Zhang 2018ChinaEast AsianCAD717/612500/184/33456/149/70.1778**rs17300539 G/A**    GG/GA/AA  Ambroziak 2018PolandCaucasianMI193/153169/23/1130/23/00.3157Chiodini 2010ItalyCaucasianMI1002/503827/165/10414/87/20.2527Gable 2007UKCaucasianMI529/568446/78/5458/107/30.2208Oliveira 2012BrazilMixedCAD449/153388/56/5131/22/00.3387Zhang 2018ChinaEast AsianCAD717/612614/100/3542/67/30.5538[^1] 10.1080/21623945.2019.1595270-F0001Figure 1.Flowchart of study selection for the present study.

Overall and subgroup analyses {#S0003-S2002}
-----------------------------

Results of overall and subgroup analyses are summarized in [Table 2](#T0002). To be brief, significant associations with the susceptibility to CAD were detected for rs266729 (overdominant model: *p* = 0.03, odds ratio \[OR\] = 1.11, 95% confidence interval \[CI\] 1.01--1.22), rs822395 (recessive model: *p* = 0.007, OR = 1.21, 95% CI 1.05--1.40) and rs2241766 (dominant model: *p* = 0.0009, OR = 0.82, 95% CI 0.73--0.92; recessive model: *p* = 0.04, OR = 1.29, 95% CI 1.02--1.64; allele model: *p* \< 0.0001, OR = 0.80, 95% CI 0.73--0.88) polymorphisms in overall analyses. Further subgroup analyses by ethnicity revealed that rs1501299 polymorphism was significantly associated with the susceptibility to CAD in East Asians, while rs2241766 polymorphism was significantly associated with the susceptibility to CAD in Caucasians, East Asians and South Asians. No any other positive results were observed in overall and subgroup analyses (see [Table 2](#T0002) and supplementary Figure 1).10.1080/21623945.2019.1595270-T0002Table 2.Results of overall and subgroup analyses for *ADIPOQ* polymorphisms and CAD.PopulationSample sizeDominant comparisonRecessive comparisonOverdominant comparisonAllele comparison*p* Value OR (95% CI) *I*^2^ statistic*p* Value OR (95% CI) *I*^2^ statistic*p* Value OR (95% CI) *I*^2^ statistic*p* Value OR (95% CI) *I*^2^ statistic**rs266729 C/G** CC vs. CG + GGGG vs. CC + CGCG vs. CC + GGC vs. GOverall8461/11,3180.06 0.90 (0.81--1.01) 62%0.69 1.03 (0.91--1.16) 20%**0.03 1.11 (1.01--1.22**) 52%0.20 0.94 (0.86--1.03) 65%Caucasian4151/49410.19 0.94 (0.86--1.03) 6%0.93 1.01 (0.84--1.21) 28%0.20 1.06 (0.97--1.16) 8%0.40 0.97 (0.90--1.04) 36%East Asian3970/60350.12 0.85 (0.70--1.04) 79%0.64 1.04 (0.88--1.24) 34%0.09 1.16 (0.98--1.38) 71%0.16 0.89 (0.76--1.05) 79%MI4744/46220.11 0.87 (0.74--1.03) 70%0.47 1.07 (0.90--1.27) 0%0.18 1.13 (0.95--1.34) 71%0.08 0.90 (0.80--1.01) 60%**rs822395 A/C** AA vs. AC + CCCC vs. AA + ACAC vs. AA + CCA vs. COverall4381/70340.83 1.01 (0.93--1.10) 0%**0.007 1.21 (1.05--1.40)** 46%0.07 0.93 (0.85--1.01) 14%0.30 0.97 (0.91--1.03) 27%Caucasian2017/21650.63 0.97 (0.86--1.10) 0%0.39 1.09 (0.89--1.34) 0%0.97 1.00 (0.88--1.13) 0%0.45 0.97 (0.88--1.06) 0%East Asian1634/32540.36 1.07 (0.93--1.24) 42%0.20 1.20 (0.91--1.59) 39%0.11 0.89 (0.77--1.03) 33%0.75 1.03 (0.85--1.25) 55%**rs1501299 G/T** GG vs. GT + TTTT vs. GG + GTGT vs. GG + TTG vs. TOverall11,544/15,6420.30 0.94 (0.84--1.05) 73%0.42 0.94 (0.80--1.10) 57%0.08 1.09 (0.99--1.19) 60%0.71 0.98 (0.90--1.08) 76%Caucasian5481/51070.82 1.01 (0.93--1.09) 39%0.12 0.80 (0.61--1.06) 67%0.29 1.04 (0.96--1.13) 2%0.47 1.04 (0.93--1.17) 64%East Asian4074/78140.08 0.82 (0.66--1.03) 82%**0.03 1.20 (1.02--1.42)** 40%0.10 1.18 (0.97--1.43) 76%0.14 0.88 (0.74--1.04) 80%South Asian479/6450.88 1.04 (0.61--1.77) 78%0.97 0.99 (0.68--1.45) 42%0.79 0.95 (0.65--1.38) 55%0.90 1.03 (0.68--1.56) 80%MI4159/58830.67 1.04 (0.87--1.23) 65%0.63 0.91 (0.63--1.32) 74%0.42 0.96 (0.88--1.05) 47%0.71 1.03 (0.88--1.21) 75%**rs2241766 T/G** TT vs. TG + GGGG vs. TT + TGTG vs. TT + GGT vs. GOverall10,135/11,577**0.0009 0.82 (0.73--0.92)** 67%**0.04 1.29 (1.02--1.64)** 63%0.08 1.12 (0.99--1.27) 71%**\<0.0001 0.80 (0.73--0.88)** 67%Caucasian2771/21060.09 0.89 (0.79--1.02) 27%0.39 0.87 (0.62--1.20) 0%**0.04 1.15 (1.01--1.32)** 33%0.24 0.93 (0.84--1.05) 20%East Asian4856/6280**0.02 0.80 (0.66--0.96)** 77%0.06 1.35 (0.99--1.84) 68%0.30 1.12 (0.90--1.40) 83%**0.0006 0.80 (0.71--0.91)** 66%South Asian959/960**0.04 0.69 (0.48--0.99)** 66%**\<0.0001 2.67 (1.82--3.91)** 39%0.76 1.05 (0.76--1.46) 56%**0.01 0.64 (0.45--0.91)** 76%MI1869/14070.19 0.90 (0.77--1.05) 0%0.11 0.68 (0.43--1.09) 18%0.06 1.16 (0.99--1.36) 30%0.48 0.95 (0.83--1.09) 0%**rs17300539 A/G** AA vs. AG + GGGG vs. AA + AGAG vs. AA + GGA vs. GOverall2890/19890.73 1.03 (0.88--1.21) 27%0.12 1.86 (0.85--4.10) 0%0.46 0.94 (0.80--1.11) 40%0.89 1.01 (0.87--1.18) 9%Caucasian1724/12240.19 1.14 (0.94--1.39) 0%0.12 2.17 (0.81--5.82) 0%0.09 0.84 (0.69--1.03) 0%0.37 1.09 (0.90--1.31) 0%MI1724/12240.19 1.14 (0.94--1.39) 0%0.12 2.17 (0.81--5.82) 0%0.09 0.84 (0.69--1.03) 0%0.37 1.09 (0.90--1.31) 0%[^2]

Sensitivity analyses {#S0003-S2003}
--------------------

We performed sensitivity analyses by excluding studies that deviated from HWE. No alterations of results were detected in sensitivity analyses, which suggested that our findings were statistically reliable.

Publication biases {#S0003-S2004}
------------------

Publication biases were evaluated with funnel plots. We did not find obvious asymmetry of funnel plots in any comparisons, which indicated that our findings were unlikely to be impacted by severe publication biases (see supplementary Figure 2).

Discussion {#S0004}
==========

To the best of our knowledge, this is so far the most comprehensive meta-analysis on associations between *ADIPOQ* polymorphisms and CAD, and our pooled analyses demonstrated that rs266729, rs822395, rs1501299 and rs2241766 polymorphisms were all significantly correlated with the susceptibility to CAD in certain populations.

There are several points that need to be addressed about this meta-analysis. First, previous experimental studies showed that mutant alleles of investigated polymorphisms were correlated with decreased adiponectin generation, which may partially explain our positive findings \[[12](#CIT0012)--[19](#CIT0019)\]. Second, it is also notable that the trends of associations in different ethnicities were not always consistent, and this may be attributed to ethnic differences in genotypic distributions of investigated polymorphisms. However, it is also possible that these inconsistent findings may have resulted from a complex interaction of both genetic and environmental factors. Third, the pathogenic mechanism of CAD is highly complex, and hence, it is unlikely that a single genetic polymorphism could significantly contribute to its development. As a result, to better illustrate potential associations of certain genetic polymorphisms with CAD, we strongly recommend further studies to perform haplotype analyses and explore potential gene--gene interactions.

Some limitations of this meta-analysis should also be noted when interpreting our findings. First, our pooled analyses were based on unadjusted estimations due to lack of raw data, and we have to admit that failure to perform further adjusted analyses may impact the reliability of our findings \[[22](#CIT0022),[23](#CIT0023)\]. Second, since our pooled analyses were based on case--control studies, despite our positive findings, future prospective studies are still needed to examine whether there is a direct causal relationship between *ADIPOQ* polymorphisms and CAD \[[24](#CIT0024),[25](#CIT0025)\]. Third, associations between *ADIPOQ* polymorphisms and CAD may also be modified by gene--gene and gene--environmental interactions. However, most studies did not consider these potential interactions, which impeded us to conduct relevant analyses \[[26](#CIT0026),[27](#CIT0027)\]. Considering the above-mentioned limitations, our findings should be interpreted with caution.

In conclusion, our meta-analysis suggested that rs266729, rs822395, rs1501299 and rs2241766 polymorphisms were all significantly correlated with the susceptibility to CAD in certain populations. However, further well-designed studies are still warranted to confirm our findings.
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###### Supplemental Material

[^1]: CAD: coronary artery disease; MI: myocardial infarction; ACS: acute coronary syndrome; HWE:Hardy-Weinberg Hardy--Weinberg equilibrium; NOS: Newcastle-Ottawa Newcastle--Ottawa scale; NA: not available.

[^2]: OR: odds ratio; CI: confidence interval; NA: not available; CAD: coronary artery disease; MI: myocardial infarction.

    The values in bold represent there are statistically significant differences between cases and controls.
